癌症研究
层粘连蛋白
翻译(生物学)
生物
细胞生物学
基因
细胞外基质
信使核糖核酸
生物化学
作者
Jianjuan Zhang,Feiyang Ji,Yuting Tan,Lei Zhao,Yongzhi Zhao,Jiaxin Liu,Liyuan Shao,Jiong Shi,Meihua Ye,Xianglei He,Jianping Jin,Bin Zhao,Jun Huang,Stephanie Roessler,Xin Zheng,Junfang Ji
标识
DOI:10.1002/advs.202309010
摘要
Abstract Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal biliary epithelial cancer in the liver. Here, Laminin subunit gamma‐2 ( LAMC2 ) with important oncogenic roles in iCCA is discovered. In a total of 231 cholangiocarcinoma patients (82% of iCCA patients) across four independent cohorts, LAMC2 is significantly more abundant in iCCA tumor tissue compared to normal bile duct and non‐tumor liver. Among 26.3% of iCCA patients, LAMC2 gene is amplified, contributing to its over‐expression. Functionally, silencing LAMC2 significantly blocks tumor formation in orthotopic iCCA mouse models. Mechanistically, it promotes EGFR protein translation via interacting with nascent unglycosylated EGFR in the endoplasmic reticulum (ER), resulting in activated EGFR signaling. LAMC2 ‐mediated EGFR translation also depends on its interaction with the ER chaperone BiP via their C‐terminus. Together LAMC2 and BiP generate a binding “pocket” of nascent EGFR and facilitate EGFR translation. Consistently, LAMC2 ‐high iCCA patients have poor prognosis in two iCCA cohorts. LAMC2 ‐high iCCA cells are highly sensitive to EGFR tyrosine kinase inhibitors (TKIs) treatment both in vitro and in vivo. Together, these data demonstrate LAMC2 as an oncogenic player in iCCA by promoting EGFR translation and an indicator to identify iCCA patients who may benefit from available EGFR‐targeted TKIs therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI